Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society
Korro Bio, Inc. (Nasdaq: KRRO), a biopharmaceutical company developing RNA-editing genetic medicines, announced presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal, October 6-9, 2024. The company will deliver one oral and two poster presentations.
The oral presentation, by Dr. Venkat Krishnamurthy, Senior VP and Head of Platform, will focus on KRRO-110, Korro's first development candidate for alpha-1 antitrypsin deficiency (AATD). This inherited disorder is caused by single nucleotide variants in the SERPINA1 gene.
The two poster presentations will cover:
- Purification of Human ADAR for evaluating oligo-directed RNA editing
- Using ADAR1 chimeric eCLIP to understand on-target and off-target behaviors of RNA editing oligonucleotides
Korro Bio, Inc. (Nasdaq: KRRO), un'azienda biofarmaceutica che sviluppa medicinali genetici per l'editing dell'RNA, ha annunciato presentazioni al 20° Congresso Annuale della Società delle Terapie Oligonucleotidali a Montreal, dal 6 al 9 ottobre 2024. L'azienda presenterà un intervento orale e due presentazioni poster.
Il intervento orale, a cura del Dr. Venkat Krishnamurthy, VP Senior e Capo della Piattaforma, si concentrerà su KRRO-110, il primo candidato di sviluppo di Korro per la deficienza di alfa-1 antitripsina (AATD). Questo disturbo ereditario è causato da varianti a singolo nucleotide nel gene SERPINA1.
Le due presentazioni poster tratteranno:
- Purificazione dell'ADAR umano per valutare l'editing dell'RNA diretto da oligonucleotidi
- Utilizzo dell'eCLIP chimera ADAR1 per comprendere i comportamenti on-target e off-target degli oligonucleotidi di editing dell'RNA
Korro Bio, Inc. (Nasdaq: KRRO), una compañía biofarmacéutica que desarrolla medicamentos genéticos de edición de ARN, anunció presentaciones en la 20ª Reunión Anual de la Sociedad de Terapias Oligonucleotídicas en Montreal, del 6 al 9 de octubre de 2024. La empresa realizará una presentación oral y dos presentaciones en formato póster.
La presentación oral, a cargo del Dr. Venkat Krishnamurthy, VP Senior y Jefe de Plataforma, se centrará en KRRO-110, el primer candidato de desarrollo de Korro para la deficiencia de alfa-1 antitripsina (AATD). Este trastorno hereditario es causado por variantes de nucleótido único en el gen SERPINA1.
Las dos presentaciones en formato póster cubrirán:
- Purificación de ADAR humano para evaluar la edición de ARN dirigida por oligonucleótidos
- Uso de eCLIP quimérico ADAR1 para entender los comportamientos on-target y off-target de los oligonucleótidos de edición de ARN
Korro Bio, Inc. (Nasdaq: KRRO)는 RNA 편집 유전자 치료제를 개발하는 생명공학 회사로 2024년 10월 6일부터 9일까지 몬트리올에서 열리는 제20회 올리고뉴클레오타이드 치료학회 연례 회의에서 발표를 할 예정이라고 발표했습니다. 회사는 하나의 구두 발표와 두 개의 포스터 발표를 진행할 것입니다.
구두 발표는 플랫폼 책임자이자 수석 부사장인 Venkat Krishnamurthy 박사가 진행하며, Korro의 첫 번째 개발 후보 KRRO-110에 초점을 맞출 것입니다. 알파-1 항트립신 결핍증 (AATD)은 SERPINA1 유전자에서 발생하는 단일 염기 변이에 의해 발생하는 유전 질환입니다.
두 개의 포스터 발표는 다음을 다룰 것입니다:
- 올리고 유도 RNA 편집을 평가하기 위한 인간 ADAR의 정제
- RNA 편집 올리고뉴클레오타이드의 목표 및 비목표 행동 이해를 위한 ADAR1 화합물 eCLIP 사용
Korro Bio, Inc. (Nasdaq: KRRO), une entreprise biopharmaceutique développant des médicaments génétiques d'édition d'ARN, a annoncé des présentations lors de la 20e réunion annuelle de la Société des thérapies oligonucleotidiques à Montréal, du 6 au 9 octobre 2024. L'entreprise réalisera une présentation orale et deux présentations sous forme d'affiche.
La présentation orale, dirigée par le Dr Venkat Krishnamurthy, VP Senior et responsable de la plateforme, se concentrera sur KRRO-110, le premier candidat au développement de Korro pour la déficience en alpha-1-antitrypsine (AATD). Ce trouble héréditaire est causé par des variantes de nucléotides uniques dans le gène SERPINA1.
Les deux présentations sous forme d'affiche porteront sur :
- Purification de l'ADAR humain pour l'évaluation de l'édition d'ARN dirigée par oligonucleotide
- Utilisation de l'eCLIP chimérique ADAR1 pour comprendre les comportements on-target et off-target des oligonucleotides d'édition d'ARN
Korro Bio, Inc. (Nasdaq: KRRO), ein biopharmazeutisches Unternehmen, das RNA-bearbeitende Gentherapeutika entwickelt, kündigte Präsentationen auf dem 20. Jahresmeeting der Oligonukleotid-Therapie-Gesellschaft in Montreal vom 6. bis 9. Oktober 2024 an. Das Unternehmen wird eine mündliche und zwei Poster-Präsentationen halten.
Die mündliche Präsentation wird von Dr. Venkat Krishnamurthy, Senior VP und Leiter der Plattform, gehalten und sich auf KRRO-110, Korros ersten Entwicklungskandidaten für die alpha-1-Antitrypsin-Mangel (AATD), konzentrieren. Diese erbliche Erkrankung wird durch einzelne Nucleotidvarianten im SERPINA1-Gen verursacht.
Die beiden Poster-Präsentationen werden sich mit folgendem befassen:
- Reinigung von menschlichem ADAR zur Bewertung von oligo-gesteuertem RNA-Editing
- Verwendung von ADAR1 chimärem eCLIP zur Untersuchung von On-Target- und Off-Target-Verhalten von RNA-Editing-Oligonukleotiden
- Korro Bio is presenting its research at a major industry conference, potentially increasing visibility and credibility
- The company has a development candidate (KRRO-110) for alpha-1 antitrypsin deficiency, indicating progress in its pipeline
- Korro is advancing its RNA editing technology, which could lead to new treatments for genetic disorders
- None.
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced one oral and two poster presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal taking place on October 6-9, 2024.
Venkat Krishnamurthy, Ph.D., Senior Vice President, Head of Platform at Korro, will deliver an oral presentation on KRRO-110, the Company’s first development candidate for the potential treatment of alpha-1 antitrypsin deficiency (AATD), an inherited genetic disorder caused by single nucleotide variants (SNVs) in the SERPINA1 gene.
Oral Presentation Information:
Title: KRRO-110, an RNA Editing Oligonucleotide For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD)
Speaker: Venkat Krishnamurthy
Date: Monday, October 7
Time: 3:20 p.m. ET
Poster Presentation Information:
Title: Purification of Human ADAR Enables Evaluation of Oligo-Directed RNA Editing in a Cell-Free Environment that Predicts In Vivo Activity
Name: Agya Karki, Ph.D., Senior Scientist
Poster Number: P133
Title: Using ADAR1 chimeric eCLIP to understand the on-target and off-target behaviors of RNA editing oligonucleotides
Name: Zhiji Ren, Ph.D., Principal Scientist
Poster Number: P228
About Korro
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to affect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro Contact Information
Investors
IR@korrobio.com
Media
Glenn Silver
FINN Partners
Glenn.silver@finnpartners.com
FAQ
What is Korro Bio's stock symbol?
What is KRRO-110 being developed to treat?
When and where is Korro Bio presenting its research in October 2024?
Who will deliver the oral presentation for Korro Bio at the conference?
